BioStock: ExpreS2ion Biotech advances breast cancer project with rights issue of SEK 53 million

ExpreS2ion Biotech is in an exciting phase following positive Phase I data for the breast cancer candidate ES2B-C001. With a successful evaluation behind it, the company is now preparing the next step for the project, while continuing to drive the rest of the pipeline and the ExpreS2 platform. To finance the continued development, the company is carrying out a rights issue of units of approximately SEK 53 million. CEO Bent U. Frandsen visited BioStock to tell more about the company's partner strategy, expected milestones in the next 12 to 18 months and how the new capital will primarily be allocated.